fbpx

InDex Pharmaceuticals – Deep Dive: Phase 3 design

InDex Pharmaceuticals - Deep Dive: Phase 3 design 27 JanuarJan 2022 12:00 - 12:30 Europe/CopenhagenOnline Event

InDex Pharmaceuticals – Deep Dive: Phase 3 design

Meet and ask questions to InDex Pharmaceuticals CEO Peter Zerhouni and CMO Dr. Thomas Knittel, when they do a deep dive into the phase lll study design `CONCLUDE´ with cobitolimod in moderate to severe left-sided ulcerative colitis.

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases, where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex Pharmaceuticals has also developed a platform of patent-protected discovery stage substances, so called DNA-based Immuno Modulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceutical is based in Stockholm, Sweden.

*Disclaimer: HC Andersen Capital receives payment from the company for a Digital IR / Corporate Visibility subscription agreement. The content does not make recommendations to buy, sell or hold. HC Andersen Capital is an information platform that connects investors and listed companies.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

InDex Pharmaceuticals - Deep Dive: Phase 3 design 27 JanuarJan 2022 12:00 - 12:30 Europe/Copenhagen
InDex Pharmaceuticals - Deep Dive: Phase 3 design Online Event
Aktier